iCAD Inc (NASDAQ:ICAD) shares rose 6.1% during trading on Wednesday . The company traded as high as $6.75 and last traded at $6.66. Approximately 18,315 shares changed hands during trading, a decline of 91% from the average daily volume of 202,933 shares. The stock had previously closed at $6.28.
Separately, ValuEngine raised iCAD from a “hold” rating to a “buy” rating in a research report on Saturday, March 30th.
The stock has a market capitalization of $120.00 million, a PE ratio of -17.50 and a beta of 1.09. The company has a 50-day moving average of $6.11. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 2.90.
Several large investors have recently made changes to their positions in the company. EAM Global Investors LLC bought a new position in shares of iCAD in the 1st quarter worth approximately $984,000. Columbia Pacific Advisors LLC raised its position in shares of iCAD by 218.0% in the 1st quarter. Columbia Pacific Advisors LLC now owns 63,600 shares of the technology company’s stock worth $329,000 after acquiring an additional 43,600 shares in the last quarter. Deutsche Bank AG raised its position in shares of iCAD by 33.5% in the 4th quarter. Deutsche Bank AG now owns 35,923 shares of the technology company’s stock worth $132,000 after acquiring an additional 9,023 shares in the last quarter. Spark Investment Management LLC bought a new position in shares of iCAD in the 1st quarter worth approximately $185,000. Finally, Advisor Group Inc. raised its position in shares of iCAD by 96,087.0% in the 4th quarter. Advisor Group Inc. now owns 22,123 shares of the technology company’s stock worth $82,000 after acquiring an additional 22,100 shares in the last quarter. 18.98% of the stock is owned by hedge funds and other institutional investors.
iCAD Company Profile (NASDAQ:ICAD)
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Featured Story: What is a management fee?
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.